论文部分内容阅读
目的:观察替米沙坦及贝那普利治疗伴高血压的老年代谢综合征(MS)患者的疗效及两者的疗效差异。方法:选择老年原发性高血压合并MS患者100例,随机分为替米沙坦组(n=50)和贝那普利组(n=50),治疗12周。治疗前后观察患者的体重指数(BMI)、收缩压(SBP)、舒张压(DBP)、空腹血糖(FBG)、三酰甘油(TG)、高密度脂蛋白(HDL-C)、空腹胰岛素(FINS)、高敏C-反应蛋白(hsCRP)、纤维蛋白原(Fg)、胰岛素抵抗指数(HOMA-IR)。结果:替米沙坦及贝那普利治疗前后,患者SBP、DBP、BMI、FBG、TG、FINS、hsCRP、HOMA-IR、Fg有显著性差异(P<0.05)。替米沙坦组SBP、TG、FINS、hsCRP、HOMA-IR治疗后较贝那普利组更低,有显著性差异(P<0.05)。结论:替米沙坦和贝那普利均可改善MS多种代谢异常,但替米沙坦能更好地改善胰岛素抵抗。
Objective: To observe the effect of telmisartan and benazepril in the treatment of senile metabolic syndrome (MS) patients with hypertension and the curative effect of the two. Methods: One hundred elderly patients with essential hypertension and MS were randomly divided into telmisartan group (n = 50) and benazepril group (n = 50) for 12 weeks. The body mass index (BMI), SBP, DBP, FBG, TG, HDL-C, FINS ), High sensitive C-reactive protein (hsCRP), fibrinogen (Fg), insulin resistance index (HOMA-IR). Results: There were significant differences in SBP, DBP, BMI, FBG, FINS, hsCRP, HOMA-IR and Fg before and after telmisartan and benazepril treatment (P <0.05). The levels of SBP, TG, FINS, hsCRP and HOMA-IR in telmisartan group were lower than those in benazepril group (P <0.05). Conclusion: Both telmisartan and benazepril can ameliorate a variety of metabolic disorders in MS, but telmisartan can better improve insulin resistance.